Neuronetics

Neuronetics, Inc. began its journey in 2003 with a singular, transformative vision: to renew lives by redefining the landscape of neurohealth. Born from a commitment to finding better solutions for patients who had lost hope in traditional psychiatric treatments, the company set out to develop non-invasive therapies that could reach the brain in ways medication could not. This dedication led to the creation of the NeuroStar Advanced Therapy System, a pioneering technology that would eventually become the first transcranial magnetic stimulation (TMS) device to receive FDA clearance for the treatment of major depressive disorder.

Over the years, Neuronetics has grown from a promising medical technology startup into a commercial-stage leader in the mental health space. The company's flagship product, NeuroStar, has delivered millions of treatments, offering a lifeline to patients battling drug-resistant depression and other psychiatric conditions. Today, Neuronetics continues to expand its impact through strategic innovations and acquisitions, such as the integration of Greenbrook TMS, further solidifying its mission to make advanced neurohealth care accessible to those who need it most. What started as a scientific breakthrough has evolved into a beacon of hope for hundreds of thousands of patients worldwide.